A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
Launched by HOFFMANN-LA ROCHE · Nov 4, 2015
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Ambulatory women
- • Diagnosis of post-menopausal osteoporosis
- • Women who have never received bisphosphonate therapy, or who have discontinued daily bisphosphonates at least 3 months prior to study entry
- Exclusion Criteria:
- • Inability to stand or sit in the upright position for greater than or equal to 60 minutes
- • Allergy to bisphosphonates;
- • Previous or current treatment with weekly or monthly bisphosphonates, or daily bisphosphonates for the last 3 months prior to study entry
Trial Officials
Clinical Trials
Study Chair
Hoffmann-La Roche
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami, Florida, United States
Decatur, Georgia, United States
Phoenix, Arizona, United States
Chicago, Illinois, United States
Seattle, Washington, United States
Des Moines, Iowa, United States
Princeton, New Jersey, United States
Mission Viejo, California, United States
Eugene, Oregon, United States
Wyomissing, Pennsylvania, United States
Indianapolis, Indiana, United States
Waterbury, Connecticut, United States
Huntsville, Alabama, United States
Newark, Delaware, United States
Houston, Texas, United States
Raleigh, North Carolina, United States
Erie, Pennsylvania, United States
Orchard Park, New York, United States
South Bend, Indiana, United States
Nashville, Tennessee, United States
Duncansville, Pennsylvania, United States
Reno, Nevada, United States
Oceanside, California, United States
Aventura, Florida, United States
Tampa, Florida, United States
Upland, California, United States
Philadelphia, Pennsylvania, United States
Richmond, Virginia, United States
Denver, Colorado, United States
Pembroke Pines, Florida, United States
Dallas, Texas, United States
West Palm Beach, Florida, United States
Warwick, Rhode Island, United States
Mount Pleasant, South Carolina, United States
Tempe, Arizona, United States
Cromwell, Connecticut, United States
Augusta, Georgia, United States
Madison, Wisconsin, United States
Wichita, Kansas, United States
Worcester, Massachusetts, United States
Florissant, Missouri, United States
Bangor, Maine, United States
St Louis, Missouri, United States
Vista, California, United States
Baltimore, Maryland, United States
Toms River, New Jersey, United States
San Diego, California, United States
Newport News, Virginia, United States
Laguna Woods, California, United States
Santa Clarita, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
